Michael N. Greco, Ph.D., joined Beta Pharma in April 2014. As Vice President of Research and Development, Dr. Greco is focused on advancing the company’s oncology pipeline and providing scientific leadership in small molecule drug discovery pertaining to the fields of oncology and virology. Prior to this role, Dr. Greco was at Johnson & Johnson for over 28 years, where he was a Scientific Director with responsibility for discovery programs targeting inflammation, cardiovascular, CNS, and metabolic disorders such as diabetes, obesity, and dyslipidemia. His leadership has led to clinical agents in the areas of inflammation and oncology. Michael N. Greco, Ph.D., joined Beta Pharma in April 2014. As Vice President of Research and Development, Dr. Greco is focused on advancing the company’s oncology pipeline and providing scientific leadership in small molecule drug discovery pertaining to the fields of oncology and virology. Prior to this role, Dr. Greco was at Johnson & Johnson for over 28 years, where he was a Scientific Director with responsibility for discovery programs targeting inflammation, cardiovascular, CNS, and metabolic disorders such as diabetes, obesity, and dyslipidemia. His leadership has led to clinical agents in the areas of inflammation and oncology.

General Science